DE69924826D1 - Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie - Google Patents

Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie

Info

Publication number
DE69924826D1
DE69924826D1 DE69924826T DE69924826T DE69924826D1 DE 69924826 D1 DE69924826 D1 DE 69924826D1 DE 69924826 T DE69924826 T DE 69924826T DE 69924826 T DE69924826 T DE 69924826T DE 69924826 D1 DE69924826 D1 DE 69924826D1
Authority
DE
Germany
Prior art keywords
associated antigen
cancer associated
immune therapy
taa
tumours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924826T
Other languages
English (en)
Other versions
DE69924826T3 (de
DE69924826T2 (de
DE69924826T8 (de
Inventor
Miles William Carroll
Kevin Alan Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269555&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69924826(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9825303.2A external-priority patent/GB9825303D0/en
Priority claimed from GBGB9901739.4A external-priority patent/GB9901739D0/en
Priority claimed from GBGB9917995.4A external-priority patent/GB9917995D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of DE69924826D1 publication Critical patent/DE69924826D1/de
Publication of DE69924826T2 publication Critical patent/DE69924826T2/de
Publication of DE69924826T3 publication Critical patent/DE69924826T3/de
Application granted granted Critical
Publication of DE69924826T8 publication Critical patent/DE69924826T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DE69924826T 1998-11-18 1999-11-18 Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie Active DE69924826T8 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9825303 1998-11-18
GBGB9825303.2A GB9825303D0 (en) 1998-11-18 1998-11-18 Vector
GBGB9901739.4A GB9901739D0 (en) 1999-01-27 1999-01-27 Polypeptide
GB9901739 1999-01-27
GBGB9917995.4A GB9917995D0 (en) 1999-07-30 1999-07-30 Polypeptide
GB9917995 1999-07-30
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy

Publications (4)

Publication Number Publication Date
DE69924826D1 true DE69924826D1 (de) 2005-05-25
DE69924826T2 DE69924826T2 (de) 2006-02-23
DE69924826T3 DE69924826T3 (de) 2008-05-29
DE69924826T8 DE69924826T8 (de) 2008-09-25

Family

ID=27269555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924826T Active DE69924826T8 (de) 1998-11-18 1999-11-18 Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie

Country Status (10)

Country Link
EP (4) EP1152060B1 (de)
JP (1) JP4907767B2 (de)
KR (1) KR20010084935A (de)
CN (1) CN1298851C (de)
AT (1) ATE293690T1 (de)
AU (1) AU766954B2 (de)
CA (1) CA2351622A1 (de)
DE (1) DE69924826T8 (de)
GB (1) GB2347932B (de)
WO (1) WO2000029428A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
AU1290001A (en) * 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
ES2256323T5 (es) 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
CN102409063A (zh) 2001-12-04 2012-04-11 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
EP1504108B1 (de) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviraler Vektor
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
AU2003239805B2 (en) 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EP1434858B2 (de) 2002-09-05 2018-12-19 Bavarian Nordic A/S Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
AU2003241006B2 (en) 2003-05-21 2011-03-24 Ares Trading S.A. TNF-like secreted protein
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
WO2006120473A2 (en) * 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Mhc class i and ii peptide antigens derived from tumour antigen 5t4
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
EP2076287A2 (de) 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
EP2076592B1 (de) 2006-10-23 2017-04-12 Medical Research Council Polymerase
EP3054991B1 (de) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
RU2016117810A (ru) 2013-10-11 2017-11-17 Асана Биосайенсис, Ллк Конъюгаты белок-полимер-лекарственное средство
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR102609624B1 (ko) 2017-03-15 2023-12-05 옥스포드 바이오메디카(유케이) 리미티드 방법
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
KR20210084546A (ko) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002077A1 (en) 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
EP0403559A1 (de) * 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Antigene
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
WO1992003568A1 (en) 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
EP0954593A1 (de) * 1996-07-25 1999-11-10 Therion Biologics Corporation Rekombinantes pockenvirus für die immunsierung gegen tumorassoziierte antigene.
GB2345063B (en) 1997-09-23 2002-07-24 Oxford Biomedica Ltd Method
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors

Also Published As

Publication number Publication date
WO2000029428A2 (en) 2000-05-25
GB2347932B (en) 2003-05-07
EP2042598A1 (de) 2009-04-01
GB2347932A (en) 2000-09-20
CN1298851C (zh) 2007-02-07
AU1394900A (en) 2000-06-05
EP1036091B1 (de) 2005-04-20
GB0014986D0 (en) 2000-08-09
EP1036091B2 (de) 2008-03-26
EP1152060B1 (de) 2015-04-15
JP2002530060A (ja) 2002-09-17
CA2351622A1 (en) 2000-05-25
DE69924826T3 (de) 2008-05-29
DE69924826T2 (de) 2006-02-23
ATE293690T1 (de) 2005-05-15
EP1036091A1 (de) 2000-09-20
JP4907767B2 (ja) 2012-04-04
DE69924826T8 (de) 2008-09-25
AU766954B2 (en) 2003-10-30
WO2000029428A3 (en) 2000-11-09
EP1152060A1 (de) 2001-11-07
CN1333829A (zh) 2002-01-30
EP1160323A1 (de) 2001-12-05
KR20010084935A (ko) 2001-09-07

Similar Documents

Publication Publication Date Title
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
IL144371A0 (en) Her-2/neu fusion proteins
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69435223D1 (de) Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
IL138075A0 (en) Vaccines, immunotherapeutics and methods for using the same
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
ATE347904T1 (de) Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert
EP1536006A4 (de) Krebsantigene und deren nutzung
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
WO2003085087A3 (en) Modified cea nucleic acid and expression vectors
WO2004092212A3 (en) Tumor antigens bfa5 for prevention and/or treatment of cancer
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
WO2023192990A3 (en) Antibodies against human siglec-9 and use thereof for immunotherapy
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
ATE506444T1 (de) Modifizierter cea/b7-vektor
EP1214942A3 (de) Verwendung von mit Bacteriophagen, die ein tumorspezifisches und/oder tumorassoziliertes Antigen auf ihrer Oberfläche tragen, beladenen dendritischen Zellen zur Behandlung von Tumoren
Demiroğlu Is prevention of cancer possible with tumor-specific vaccines?

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings